Literature DB >> 8977304

Tumor necrosis factor receptor p55 mediates deletion of peripheral cytotoxic T lymphocytes in vivo.

D E Speiser1, E Sebzda, T Ohteki, M F Bachmann, K Pfeffer, T W Mak, P S Ohashi.   

Abstract

Cellular death of activated lymphocytes down-regulates immune responses and is involved in maintaining self tolerance. Signals associated with ligation of the membrane molecule Fas lead to lymphocyte apoptosis, but additional, Fas-independent mechanisms have been postulated. Here, we show a marked expansion and prolonged persistence of functional activated cytotoxic T cells in mice lacking the tumor necrosis factor (TNF) receptor p55. In the absence of this receptor, peripheral lymphocyte apoptosis was significantly reduced in vivo. The prolonged thymocyte survival was associated with functional anergy, since the T cells no longer proliferated in vitro when stimulated with peptide antigen. However, specific cytotoxic effector function was easily detected in vitro. We conclude that the TNF receptor p55 is involved in peripheral T cell deletion in vivo.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8977304     DOI: 10.1002/eji.1830261235

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

Review 1.  The role of Fas-FasL in CD8+ T-cell-mediated insulin-dependent diabetes mellitus (IDDM).

Authors:  H T Kreuwel; L A Sherman
Journal:  J Clin Immunol       Date:  2001-01       Impact factor: 8.317

2.  The Bcl-2 family pro-apoptotic molecule, BNIP3 regulates activation-induced cell death of effector cytotoxic T lymphocytes.

Authors:  J Wan; D Martinvalet; X Ji; C Lois; S M Kaech; U H Von Andrian; J Lieberman; R Ahmed; N Manjunath
Journal:  Immunology       Date:  2003-09       Impact factor: 7.397

Review 3.  Gene therapy for rheumatoid arthritis. Theoretical considerations.

Authors:  Y Chernajovsky; A Annenkov; C Herman; K Triantaphyllopoulos; D Gould; H Dreja; S P Moyes; J L Croxford; R A Mageed; O L Podhajcer; D Baker
Journal:  Drugs Aging       Date:  1998-01       Impact factor: 3.923

4.  A dominant interfering mutant of FADD/MORT1 enhances deletion of autoreactive thymocytes and inhibits proliferation of mature T lymphocytes.

Authors:  K Newton; A W Harris; M L Bath; K G Smith; A Strasser
Journal:  EMBO J       Date:  1998-02-02       Impact factor: 11.598

5.  Trypanosoma cruzi infection in tumor necrosis factor receptor p55-deficient mice.

Authors:  E Castaños-Velez; S Maerlan; L M Osorio; F Aberg; P Biberfeld; A Orn; M E Rottenberg
Journal:  Infect Immun       Date:  1998-06       Impact factor: 3.441

Review 6.  The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.

Authors:  G Kollias; E Douni; G Kassiotis; D Kontoyiannis
Journal:  Ann Rheum Dis       Date:  1999-11       Impact factor: 19.103

7.  Induction of cell death by tumour necrosis factor (TNF) receptor 2, CD40 and CD30: a role for TNF-R1 activation by endogenous membrane-anchored TNF.

Authors:  M Grell; G Zimmermann; E Gottfried; C M Chen; U Grünwald; D C Huang; Y H Wu Lee; H Dürkop; H Engelmann; P Scheurich; H Wajant; A Strasser
Journal:  EMBO J       Date:  1999-06-01       Impact factor: 11.598

Review 8.  Exploring the Pathogenic Role and Therapeutic Implications of Interleukin 2 in Autoimmune Hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2020-08-24       Impact factor: 3.199

9.  CD4(+)CD25(+) regulatory T cells resist a novel form of CD28- and Fas-dependent p53-induced T cell apoptosis.

Authors:  Nagendra Singh; Mutsumi Yamamoto; Mariko Takami; Yoichi Seki; Mayuko Takezaki; Andrew L Mellor; Makio Iwashima
Journal:  J Immunol       Date:  2009-11-30       Impact factor: 5.422

10.  Dose-dependent lymphocyte apoptosis following respiratory infection with Vaccinia virus.

Authors:  Nicole L Yates; Rama D Yammani; Martha A Alexander-Miller
Journal:  Virus Res       Date:  2008-08-23       Impact factor: 3.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.